Inactive Instrument

Press Releases DermTech, Inc. Nasdaq

Equities

VGG2379F1247

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

DermTech Reports First-Quarter 2024 Financial Results	May. 14	BU
DermTech : Accelaration/Increase of Financial Obligation - Form 8-K	May. 10	PU
DermTech to Explore Strategic Alternatives and Implement Restructuring Plan	Apr. 18	BU
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Apr. 01	BU
DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology	Mar. 11	AQ
DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology	Mar. 08	BU
DermTech : 2023 Q4 Transcript	Feb. 29	PU
DermTech Reports Fourth-Quarter 2023 Financial Results	Feb. 29	BU
DermTech Announces Release Date for Fourth-quarter 2023 Financial Results	Feb. 13	BU
DermTech Announces Additional Restructuring Actions to Focus on Revenue Growth and Streamline Operations	Jan. 31	BU
DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test across All Skin Types	Jan. 19	AQ
DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test (DMT) Across All Skin Types	Jan. 18	BU
DERMTECH SIMPLIFIES THE DERMTECH MELANOMA TEST BY DISCONTINUING THE OPTIONAL TERT ADD-ON ASSAY	Jan. 17	AQ
DermTech Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-on Assay	Jan. 16	BU
DERMTECH ANNOUNCES POSITIVE TOPLINE RESULTS FROM TRUST 2 STUDY EVALUATING THE DERMTECH MELANOMA TEST	Jan. 09	AQ
DermTech Announces Positive Topline Results From Trust 2 Study Evaluating the DermTech Melanoma Test (DMT)	Jan. 08	BU
DERMTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating DermTech, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm	Dec. 28	BU
DMTK DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages DermTech, Inc. Investors to Secure Counsel Before Important December 15 Deadline in Securities Class Action – DMTK	Dec. 15	BU
DERMTECH ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)	Dec. 15	AQ
DMTK DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages DermTech, Inc. Investors to Secure Counsel Before Important December 15 Deadline in Securities Class Action - DMTK	Dec. 14	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases DermTech, Inc. Nasdaq

Equities

VGG2379F1247

Press Releases

Filters